Lipedema stage affects adipocyte hypertrophy, subcutaneous adipose tissue inflammation and interstitial fibrosis.
adipose tissue
fibrosis
inflammation
lipedema
lipoedema
macrophages
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
05
2023
accepted:
10
07
2023
medline:
16
8
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
epublish
Résumé
Lipedema is a painful subcutaneous adipose tissue (SAT) disease characterized by adipocyte hypertrophy, immune cell recruitment, and fibrosis in the affected areas. These features are thought to contribute to the development and progression of the condition. However, the relationship between lipedema disease stage and the associated adipose tissue changes has not been determined so far. SAT biopsies of 32 lipedema patients, ranging across the pathological stages I to III, and 14 BMI- and age-matched controls were harvested from lipedema-affected thighs and non-symptomatic lower abdominal regions. Histological and immunohistochemical (IHC) staining and expression analysis of markers for adipogenesis, immunomodulation, and fibrosis were performed on the tissue biopsies. Lipedema patients showed increased adipocyte areas and a stage-dependent shift towards larger cell sizes in the thighs. Lipedema SAT was linked with increased interstitial collagen accumulation in the thighs, but not the lower abdominal region when compared to controls. There was a trend toward progressive SAT fibrosis of the affected thighs with increasing lipedema stage. Elevated gene expression levels of macrophage markers were found for thigh SAT biopsies, but not in the abdominal region. IHC staining of lipedema thigh biopsies confirmed a transiently elevated macrophage polarization towards an M2-like (anti-inflammatory) phenotype. In summary, lipedema SAT is associated with stage-dependent adipocyte hypertrophy, stage-progressive interstitial fibrosis and elevated proportion of M2-like macrophages. The character of the inflammatory response differs from primary obesity and may possess an essential role in the development of lipedema.
Identifiants
pubmed: 37575263
doi: 10.3389/fimmu.2023.1223264
pmc: PMC10417720
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1223264Informations de copyright
Copyright © 2023 Kruppa, Gohlke, Łapiński, Garcia-Carrizo, Soultoukis, Infanger, Schulz and Ghods.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Metabolism. 2017 Jul;72:120-143
pubmed: 28641779
J Clin Endocrinol Metab. 2007 Mar;92(3):1023-33
pubmed: 17164304
Methods Enzymol. 2014;537:93-122
pubmed: 24480343
J Clin Endocrinol Metab. 2006 Jul;91(7):2776-81
pubmed: 16608891
J Lipid Res. 2016 Oct;57(10):1899-1905
pubmed: 27481939
Plast Reconstr Surg. 2022 Mar 1;149(3):529e-541e
pubmed: 35089257
Lymphology. 2011 Dec;44(4):178-82
pubmed: 22458119
Am J Physiol Endocrinol Metab. 2010 Dec;299(6):E1016-27
pubmed: 20841504
Obes Surg. 2020 Dec;30(12):5086-5100
pubmed: 33021706
J Clin Endocrinol Metab. 2011 Jan;96(1):E73-82
pubmed: 21047918
Physiol Rev. 2018 Oct 1;98(4):1911-1941
pubmed: 30067159
Diabetes. 2014 Nov;63(11):3785-97
pubmed: 24947352
Front Endocrinol (Lausanne). 2022 Oct 31;13:1000094
pubmed: 36387874
Diabetes. 2010 Nov;59(11):2817-25
pubmed: 20713683
Lymphology. 2008 Dec;41(4):161-6
pubmed: 19306662
J Clin Invest. 2007 Jan;117(1):175-84
pubmed: 17200717
Obesity (Silver Spring). 2014 Aug;22(8):1807-13
pubmed: 24719315
Endocr Rev. 2022 Jan 12;43(1):35-60
pubmed: 34100954
Horm Mol Biol Clin Investig. 2018 Mar 9;33(1):
pubmed: 29522416
Diabetes. 2005 Aug;54(8):2277-86
pubmed: 16046292
J Obes. 2019 Mar 3;2019:8747461
pubmed: 30949365
Diabetologia. 2016 Mar;59(3):560-70
pubmed: 26607638
PLoS One. 2014 Aug 22;9(8):e105262
pubmed: 25148116
J Clin Invest. 2003 Dec;112(12):1821-30
pubmed: 14679177
Obesity (Silver Spring). 2016 Mar;24(3):597-605
pubmed: 26916240
Dermatol Ther. 2020 Nov;33(6):e14534
pubmed: 33184945
Womens Health Rep (New Rochelle). 2020 Oct 14;1(1):480-487
pubmed: 33786515
FASEB J. 2015 Jul;29(7):3027-39
pubmed: 25852044
Handchir Mikrochir Plast Chir. 2018 Dec;50(6):400-411
pubmed: 30620978
Obesity (Silver Spring). 2013 Dec;21(12):2562-70
pubmed: 23512827
Sci Rep. 2020 Jul 2;10(1):10947
pubmed: 32616854
Nutr Metab Cardiovasc Dis. 2009 Dec;19(10):736-43
pubmed: 19356913
Int J Mol Sci. 2022 Jun 14;23(12):
pubmed: 35743063
J Cutan Pathol. 2004 Feb;31(2):205-9
pubmed: 14690469
Int J Mol Sci. 2021 Mar 24;22(7):
pubmed: 33805070
BMJ Case Rep. 2017 Aug 23;2017:
pubmed: 28835426
Obesity (Silver Spring). 2008 Jul;16(7):1487-92
pubmed: 18451782
J Cutan Pathol. 2009 Dec;36(12):1293-8
pubmed: 19281484
J Pediatr. 2007 Dec;151(6):647-52
pubmed: 18035146
Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):685-91
pubmed: 18239153
Nat Rev Endocrinol. 2015 Feb;11(2):90-100
pubmed: 25365922
J Surg Res. 2020 Sep;253:294-303
pubmed: 32407981
Circulation. 2008 Oct 28;118(18):1837-47
pubmed: 18852364
Lymphology. 2008 Mar;41(1):40-4
pubmed: 18581957
Dtsch Arztebl Int. 2020 Jun 1;117(22-23):396-403
pubmed: 32762835
J Endocrinol Invest. 2007 Mar;30(3):210-4
pubmed: 17505154
Obesity (Silver Spring). 2010 Dec;18(12):2354-61
pubmed: 20395951
J Clin Invest. 2003 Dec;112(12):1796-808
pubmed: 14679176
Nat Rev Immunol. 2011 Oct 10;11(11):738-49
pubmed: 21984069